Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMGEN INC.

(AMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2021 04/13/2021 04/14/2021 04/15/2021 04/16/2021 Date
248.94(c) 249.95(c) 249.62(c) 255.13(c) 255.71(c) Last
1 721 957 1 766 133 1 753 827 2 366 334 2 710 283 Volume
0.00% +0.41% -0.13% +2.21% +0.23% Change
More quotes
Financials (USD)
Sales 2021 26 461 M - -
Net income 2021 7 614 M - -
Net Debt 2021 17 631 M - -
P/E ratio 2021 19,2x
Yield 2021 2,70%
Sales 2022 27 348 M - -
Net income 2022 8 466 M - -
Net Debt 2022 15 165 M - -
P/E ratio 2022 17,0x
Yield 2022 2,92%
Capitalization 147 B 147 B -
EV / Sales 2021 6,23x
EV / Sales 2022 5,94x
Nbr of Employees 24 300
Free-Float 99,8%
More Financials
Company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN... 
Sector
Pharmaceuticals
Calendar
04/27Earnings Release
More about the company
Notations Surperformance© of Amgen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about AMGEN INC.
04/16AMGEN INC  : Completion of Acquisition or Disposition of Assets, Regulation FD D..
AQ
04/14AMGEN  : Stands With PhRMA to Increase Diversity in Clinical Trials
PU
04/12AMGEN  : Members of Amgen's Senior Leadership Receive Their COVID-19 Vaccines
PU
04/09AMGEN  : Discussing the Pivotal Role Biomarker Testing Plays in Treatment of Lun..
PU
04/07AMGEN  : Tackling Adversity Through Diversity
PU
04/07PRESS RELEASE  : T-knife Therapeutics Announces the Appointment of Donald Wuchte..
DJ
04/05AMGEN  : Congratulations to Amgen's 2020 Environmental Champions!
PU
04/05AMGEN  : Olpasiran Could Potentially Drive Long-Term Growth on Expected $1.5 Bil..
MT
04/05AMGEN  : Oppenheimer Adjusts Amgen PT to $275 From $266, Maintains Outperform Ra..
MT
04/01AMGEN  : Widespread COVID-19 Vaccination Underway for Amgen Staff in Puerto Rico
PU
03/31AMGEN  : Gloves on Gloves? Frocks on Frocks? That's Biotech Manufacturing, With ..
PU
03/30Amgen to Acquire Rodeo Therapeutics Corp.
DJ
03/30AMGEN  : Seen Logging 25% Revenue Compound Annual Growth in Asia Pacific Over 10..
MT
03/30AMGEN  : Agrees to Acquire Rodeo Therapeutics
MT
03/30AMGEN  : to Acquire Rodeo Therapeutics Corporation
PR
More news
News in other languages on AMGEN INC.
04/16Lilly pide a FDA que no permita uso de terapia COVID-19 bamlanivimab sin etes..
04/15Morning Briefing International
03/30Aktien New York: Renditeanstieg bremst vor allem an der Nasdaq
03/30IRW-PRESS  : Cardiol Therapeutics Inc. : Cardiol Therapeutics ernennt Dr. Andrew..
03/05Aktien Schweiz Schluss: SMI mit happigen Abgaben zum Wochenschluss
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 253,61 $
Last Close Price 255,71 $
Spread / Highest target 17,7%
Spread / Average Target -0,82%
Spread / Lowest Target -27,7%
EPS Revisions
Managers and Directors
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.10.96%147 238
JOHNSON & JOHNSON3.09%427 130
ROCHE HOLDING AG0.16%289 376
PFIZER INC.2.15%215 150
NOVARTIS AG-3.73%198 528
MERCK & CO., INC.-5.29%196 100